JP2024527220A5 - - Google Patents

Info

Publication number
JP2024527220A5
JP2024527220A5 JP2023566569A JP2023566569A JP2024527220A5 JP 2024527220 A5 JP2024527220 A5 JP 2024527220A5 JP 2023566569 A JP2023566569 A JP 2023566569A JP 2023566569 A JP2023566569 A JP 2023566569A JP 2024527220 A5 JP2024527220 A5 JP 2024527220A5
Authority
JP
Japan
Prior art keywords
composition according
pro
peptide
composition
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566569A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527220A (ja
Filing date
Publication date
Priority claimed from KR1020210086014A external-priority patent/KR20230004135A/ko
Application filed filed Critical
Publication of JP2024527220A publication Critical patent/JP2024527220A/ja
Publication of JP2024527220A5 publication Critical patent/JP2024527220A5/ja
Pending legal-status Critical Current

Links

JP2023566569A 2021-06-30 2022-06-30 グルカゴン、glp-1及びgip受容体の全てに対して活性を有する三重活性体を含む組み合わせ物の治療学的用途 Pending JP2024527220A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2021-0086014 2021-06-30
KR1020210086014A KR20230004135A (ko) 2021-06-30 2021-06-30 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도
PCT/KR2022/009449 WO2023277620A1 (ko) 2021-06-30 2022-06-30 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도

Publications (2)

Publication Number Publication Date
JP2024527220A JP2024527220A (ja) 2024-07-24
JP2024527220A5 true JP2024527220A5 (cg-RX-API-DMAC7.html) 2025-07-07

Family

ID=84690475

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566569A Pending JP2024527220A (ja) 2021-06-30 2022-06-30 グルカゴン、glp-1及びgip受容体の全てに対して活性を有する三重活性体を含む組み合わせ物の治療学的用途

Country Status (11)

Country Link
US (1) US20240293512A1 (cg-RX-API-DMAC7.html)
EP (1) EP4364750A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024527220A (cg-RX-API-DMAC7.html)
KR (1) KR20230004135A (cg-RX-API-DMAC7.html)
CN (1) CN117615775A (cg-RX-API-DMAC7.html)
AU (1) AU2022302809A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023022445A2 (cg-RX-API-DMAC7.html)
CA (1) CA3216330A1 (cg-RX-API-DMAC7.html)
IL (1) IL308347A (cg-RX-API-DMAC7.html)
MX (1) MX2023012935A (cg-RX-API-DMAC7.html)
WO (1) WO2023277620A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US20130035281A1 (en) * 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
JP6712323B2 (ja) * 2015-12-31 2020-06-17 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、glp−1及びgip受容体のすべてに活性を有する三重活性体
SG10202109721PA (en) * 2016-03-10 2021-10-28 Medimmune Ltd Glucagon and glp-1 co-agonists for the treatment of obesity
JOP20190095A1 (ar) * 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
AR110300A1 (es) * 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip
JP7005638B2 (ja) * 2017-01-27 2022-02-04 エヌジーエム バイオファーマシューティカルス,インコーポレーテッド グルカゴン受容体結合タンパク質及びその使用方法
WO2020071865A1 (ko) * 2018-10-04 2020-04-09 한미약품 주식회사 글루카곤 및 이를 포함하는 조합물의 치료학적 용도
WO2020130749A1 (ko) * 2018-12-21 2020-06-25 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 및 인슐린을 포함하는 약학 조성물
WO2020142365A1 (en) * 2018-12-31 2020-07-09 Christos Mantzoros Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
MX2021015927A (es) * 2019-06-28 2022-04-18 Hanmi Pharm Ind Co Ltd Uso terapéutico de agonista trigonal de los receptores de glucagón, glp-1 y gip, o conjugado de los mismos para enfermedades hepáticas.
JP2023537895A (ja) * 2020-08-14 2023-09-06 ハンミ ファーマシューティカル カンパニー リミテッド 三重活性体持続型結合体を有効成分として含む薬学組成物

Similar Documents

Publication Publication Date Title
JP7341263B2 (ja) オキシントモジュリン誘導体を含む糖尿病又は肥満性糖尿病の治療用組成物
JP6076902B2 (ja) 新規な持続型グルカゴン結合体およびこれを含む肥満の予防および治療用薬学的組成物
KR101201339B1 (ko) 인간 epo 미메틱 힌지 코어 미메티바디, 조성물, 방법및 용도
JP2020164534A (ja) インスリン及びglp−1/グルカゴン二重アゴニストを含む糖尿病治療用組成物
US8097586B2 (en) Modified exedins and uses thereof
US8716221B2 (en) Modified exendins and uses thereof
IL260310B1 (en) Long-term coupling of a triple agonist to glucagon/GLP–1/GIP receptors
KR20050033563A (ko) 포유동물 epo 모방 ch1 결실된 모방체, 조성물, 방법및 용도
JP2006520818A (ja) ポリエチレングリコール結合glp−1化合物
PT2356269T (pt) Composições, métodos e usos de scaffolds baseados em domínios de fibronectina tipo iii
JP7762645B2 (ja) バリアントfcドメイン及びその使用
JP2022551282A5 (cg-RX-API-DMAC7.html)
RU2677800C2 (ru) Сайт-специфичный конъюгат инсулина
JP2007514752A (ja) Glp−1医薬組成物
JP2024512418A (ja) 新規な免疫活性インターロイキン2アナログ結合体及びその製造方法
TWI922560B (zh) 新穎之三重升糖素/glp-1/gip受體促效劑及其用途
JP2024178193A (ja) インスリン及びグルカゴンを含む薬学組成物
JP2024500605A5 (cg-RX-API-DMAC7.html)
JP2024525213A5 (cg-RX-API-DMAC7.html)
JP2024507795A (ja) グルカゴン様ペプチド-1受容体アンタゴニスト
JP2023538236A5 (cg-RX-API-DMAC7.html)
JP2023537895A5 (cg-RX-API-DMAC7.html)
WO2025157263A1 (zh) 偶联物及其制备方法和用途
EP4364750A1 (en) Therapeutic use of combination comprising triple activator having activity on all of glucagon, glp-1 and gip receptor
AU2021409610A1 (en) Combination therapy of insulinotropic peptide and glp-2, for preventing or treating short bowel syndrome